Rznomics Inc., a South Korea based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, announced that it has receive...
Senhwa Biosciences, Inc. (TPEx: 6492), announced IND Submission to US FDA for the Phase I/II study of Silmitasertib (CX-4945) in combination with c...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, is proud to announce its partnership with the National Cancer Institute (...
Clinical evaluation of several modified release once-daily formulations of danuglipron resulted in encouraging pharmacokinetic data for several candi...
BioArctic AB is pleased to announce that its partner, Eisai, has received approval from the Department of Health in Hong Kong for Leqembi® (bra...
Funds to support Phase Ib clinical trial of HRX-215 in the US and an international multicenter Phase IIa clinical trial in liver regeneration Elias Pa...
Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces that the Clinical Trial Application f...
Eli Lilly and Company (NYSE: LLY) and Morphic Holding, Inc. (NASDAQ: MORF) announced a definitive agreement for Lilly to acquire Mor...
Boehringer Ingelheim and OSE Immunotherapeutics SA (OSE), a clinical stage biotech company (ISIN: FR0012127173; Mnemo: OSE), announced that Boehringer wi...
Johnson & Johnson announced positive results from the nipocalimab Phase 3 Vivacity-MG study in patients with generalized myasthenia gravis (gMG...
SCG Cell Therapy Pte Ltd (SCG), a biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today anno...
The PPD clinical research business will nearly double its laboratory footprint in northern Kentucky, add more than 250 jobs The PPD clinical research bu...
SNIPR Biome, a pioneer in the development CRISPR-Cas armed phages (CAPs) to prevent and treat bacterial infections, announced today that it has received ...
Novo Nordisk announced that the CLARION-CKD phase 3 trial failed to meet its primary endpoint and that it will recognise an impairment loss of around DKK...
© 2024 Biopharma Boardroom. All Rights Reserved.
